<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent - Zhu, J - 2021 | Cochrane Library</title> <meta content="Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent - Zhu, J - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011300.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent - Zhu, J - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011300.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011300.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent" name="citation_title"/> <meta content="Jianwei Zhu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Yun Yuan" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Xiaoyu Wan" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Dan Yin" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Rui Li" name="citation_author"/> <meta content="Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Wenwen Chen" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Chen Suo" name="citation_author"/> <meta content="Fudan University, Ministry of Education" name="citation_author_institution"/> <meta content="Huan Song" name="citation_author"/> <meta content="songhuan@wchscu.cn" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011300.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011300.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011300.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011300.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Carcinoma, Non-Small-Cell Lung [drug therapy]; Chemoradiotherapy; Immunotherapy; *Lung Neoplasms [drug therapy]; Progression-Free Survival; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011300.pub3&amp;doi=10.1002/14651858.CD011300.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011300\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011300\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","pt","ko","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011300.pub3",title:"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non\\u2010small cell lung cancer treated with surgery or radiotherapy with curative intent",firstPublishedDate:"Dec 6, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Lung Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011300.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011300.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011300.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011300.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011300.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011300.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011300.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011300.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011300.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011300.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2744 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011300.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0074"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/appendices#CD011300-sec-0079"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/table_n/CD011300StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/table_n/CD011300StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0004">Jianwei Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0005">Yun Yuan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0006">Xiaoyu Wan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0007">Dan Yin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0008">Rui Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0009">Wenwen Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0010">Chen Suo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information#CD011300-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Huan Song</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information/en#CD011300-sec-0086">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011300.pub3">https://doi.org/10.1002/14651858.CD011300.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011300-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011300-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011300-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011300-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011300-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011300-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011300-abs-0004">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011300-abs-0001" lang="en"> <section id="CD011300-sec-0001"> <h3 class="title" id="CD011300-sec-0001">Background</h3> <p>Non‐small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For people with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. This is an update of a Cochrane Review first published in 2017 and it includes two new randomised controlled trials (RCTs). </p> </section> <section id="CD011300-sec-0002"> <h3 class="title" id="CD011300-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) among  people  with localised NSCLC of stages I to III who received curative intent of radiotherapy or surgery. </p> </section> <section id="CD011300-sec-0003"> <h3 class="title" id="CD011300-sec-0003">Search methods</h3> <p>We searched the following databases (from inception to 19 May 2021): CENTRAL, MEDLINE, Embase, CINAHL, and five trial registers. We also searched conference proceedings and reference lists of included trials. </p> </section> <section id="CD011300-sec-0004"> <h3 class="title" id="CD011300-sec-0004">Selection criteria</h3> <p>We included RCTs conducted in adults (≥ 18 years) diagnosed with  NSCLC stage I to III after surgical resection, and those with unresectable locally advanced stage III NSCLC receiving radiotherapy with curative intent. We included participants who underwent primary surgical treatment, postoperative radiotherapy or chemoradiotherapy if the same strategy was provided for both intervention and control groups. </p> </section> <section id="CD011300-sec-0005"> <h3 class="title" id="CD011300-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected eligible trials, assessed risk of bias, and extracted data. We used survival analysis to pool time‐to‐event data, using hazard ratios (HRs). We used risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous data, with 95% confidence intervals (CIs). Due to clinical heterogeneity (immunotherapeutic agents with different underlying mechanisms), we combined data by applying random‐effects models. </p> </section> <section id="CD011300-sec-0006"> <h3 class="title" id="CD011300-sec-0006">Main results</h3> <p>We included 11 RCTs involving 5128 participants (this included 2 new trials with 188 participants since the last search dated 20 January 2017). Participants who underwent surgical resection or received curative radiotherapy were randomised to either an immunotherapy group or a control group. The immunological interventions were active immunotherapy Bacillus Calmette‐Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour‐infiltrating lymphocytes (TIL), dendritic cell/cytokine‐induced killer (DC/CIK), antigen‐specific cancer vaccines (melanoma‐associated antigen 3 (MAGE‐A3) and L‐BLP25), and targeted natural killer (NK) cells. Seven trials were at high risk of bias for at least one of the risk of bias domains. Three trials were at low risk of bias across all domains and one small trial was at unclear risk of bias as it provided insufficient information. We included data from nine of the 11 trials in the meta‐analyses involving 4863 participants. </p> <p>There was no evidence of a difference between the immunotherapy agents and the controls on any of the following outcomes: overall survival (HR 0.94, 95% CI 0.84 to 1.05; P = 0.27; 4 trials, 3848 participants; high‐quality evidence), progression‐free survival (HR 0.94, 95% CI 0.86 to 1.03; P = 0.19; moderate‐quality evidence), adverse events (RR 1.12, 95% CI 0.97 to 1.28; P = 0.11; 4 trials, 4126 evaluated participants; low‐quality evidence), and severe adverse events (RR 1.14, 95% CI 0.92 to 1.40; 6 trials, 4546 evaluated participants; low‐quality evidence).  </p> <p>Survival rates at different time points showed no evidence of a difference between immunotherapy agents and the controls. Survival rate at 1‐year follow‐up (RR 1.02, 95% CI 0.96 to 1.08; I<sup>2</sup> = 57%; 7 trials, 4420 participants; low‐quality evidence), 2‐year follow‐up (RR 1.02, 95% CI 0.93 to 1.12; 7 trials, 4420 participants; moderate‐quality evidence), 3‐year follow‐up (RR 0.99, 95% CI 0.90 to 1.09; 7 trials, 4420 participants; I<sup>2</sup> = 22%; moderate‐quality evidence) and at 5‐year follow‐up (RR 0.98, 95% CI 0.86 to 1.12; I<sup>2</sup> = 0%; 7 trials, 4389 participants; moderate‐quality evidence).  </p> <p>Only one trial reported overall response rates. Two trials provided health‐related quality of life results with contradicting results.  </p> </section> <section id="CD011300-sec-0007"> <h3 class="title" id="CD011300-sec-0007">Authors' conclusions</h3> <p>Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD‐1/PD‐L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011300-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011300-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011300-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011300-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011300-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011300-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011300-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011300-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011300-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011300-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011300-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011300-abs-0002" lang="en"> <h3>Effect of immunotherapy on the prognosis for stages I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent </h3> <p><b>Review question</b> </p> <p>Do treatments that help the body's immune system fight cancer cells (immunotherapy) make people with non‐small cell lung cancer (NSCLC) who have had surgery or radiotherapy aimed at a cure, live longer? </p> <p><b>Background</b> </p> <p>Many people with NSCLC, who have had surgery or radiotherapy to cure their cancer, eventually die because the cancer comes back, either in the chest, or somewhere else in the body. There have been a number of trials over the years that have looked at whether immunotherapy helps people live longer. Some seemed to show a benefit, others did not. </p> <p><b>Study characteristics</b> </p> <p>We searched four computerised databases and five trial registers to 19 May 2021. We looked for all trials that randomly allocated participants to one treatment or another (randomised controlled trials, RCTs), and included adults (aged 18 years or older) with early NSCLC (stages I to III), confirmed by laboratory testing of a sample of the tumour. We found 11 RCTs, which included over 5000 participants who had received surgery or curative radiotherapy, and were randomly allocated to receive either immunotherapy or no further treatment.  </p> <p><b>Key results</b> </p> <p>We found that giving immunotherapy, mainly vaccine‐based (aiming to activate the host immune system to induce human immune response to tumour‐specific antigens), after surgery or radiotherapy did not make people live longer. People who were given vaccine‐based immunotherapy did not seem to experience more side effects than the others. We did not find results that could tell us whether the addition of immunotherapy improved quality of life. At the moment, there is no evidence to support or refute giving immunotherapy (mainly vaccine‐based) to people with localised NSCLC (stages I to III). RCTs in progress are testing new, more promising immunotherapy drugs (e.g. checkpoint inhibitors).  </p> <p><b>Quality of the evidence</b> </p> <p>The evidence we found about overall survival and progression‐free survival was of high and moderate quality, respectively. When we looked for evidence about how many participants lived to one, two, three, or five years, it was only moderate or low quality, because the RCTs were not very well done, and their results did not agree with each other. The evidence for both any and severe adverse events was of low quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011300-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011300-sec-0074"></div> <h3 class="title" id="CD011300-sec-0075">Implications for practice</h3> <section id="CD011300-sec-0075"> <p>So far, based on this updated review, there is no evidence showing better survival outcomes associated with the addition of immunotherapy (excluding checkpoint inhibitors) for people with stages I to III NSCLC. However, the probability of experiencing adverse events may be greater for people receiving immunotherapy, especially the MAGE‐A3 vaccine. A major concern for the evidence on overall survival and progression‐free survival was the small proportion of included trials (36%; 45%) that contributed usable data for group comparisons. For yearly survival rate analyses, for which more data were available, we found no clear differences between the treatment groups for 1‐year, 2‐year, 3‐year, or 5‐year survival rates, with significant heterogeneity across the trials for the 1‐year rate, which could not be fully explained by either variation in study quality or the clinical differences in the trials. </p> <p>Based on these results, we consider that at present, there is insufficient evidence to support or negate the use of adjuvant immunotherapy (excluding checkpoint inhibitors) for people with stages I to III NSCLC. Several planned or ongoing trials that aim to treat people with stages IB to IIIA NSCLC with adjuvant checkpoint inhibitors (PD‐1/PD‐L1) may provide new evidence for the use of immunotherapy. </p> </section> <h3 class="title" id="CD011300-sec-0076">Implications for research</h3> <section id="CD011300-sec-0076"> <p>We found no ongoing clinical trials on participants with stages I to III NSCLC that could provide additional evidence on the effectiveness of vaccine‐based immunotherapy from this updated review. We identified several planned or ongoing trials with a focus on adjuvant checkpoint inhibitors (PD‐1/PD‐L1). Future efforts should be put into the development of novel, effective immunotherapy, and the detection of more useful prognostic biomarkers to guide the use of these immunotherapeutic drugs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011300-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011300-sec-0008"></div> <div class="table" id="CD011300-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immunotherapy for surgically‐treated patients with non‐small cell lung cancer (NSCLC), with or without radiotherapy with curative intent</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Immunotherapy for surgically‐treated NSCLC patients, with or without radiotherapy with curative intent</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> immunotherapy plus surgery (adjuvant chemotherapy or chemoradiotherapy was allowed, provided it was applied to both experimental and control groups)<br/><b>Comparison:</b> surgical treatment with placebo, best supportive care, no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with surgical treatment only (control group)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with immunotherapy plus surgery (experimental group)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median overall survival time ranged across control groups from 22.3 to 60.2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median overall survival time ranged across experimental groups from 25.6 to 62.0 months </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.84 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3848</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median progression‐free survival time ranged across control groups from 11.4 to 57.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median progression‐free survival time ranged across experimental groups from 14.2 to 60.5 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.86 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3861<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 1‐year survival rate</p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.96 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be partly explained by the inclusion of data from trials with high risk of bias. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>824 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>841 per 1000<br/>(792 to 891) </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 2‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.93 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000 (551 to 664)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 3‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.90 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(333 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 5‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.86 to 1.12) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4389<br/>(7 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(71 to 92) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: any</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.97 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4126<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup><br/>  </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be explained by the different agents applied in different trials. By restricting to MAGE‐A3 trials, we observed statistically significant elevation in general adverse event risk (RR 1.23, 95% CI 1.18 to 1.29; I² = 0%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>805 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>913 per 1000<br/>(791 to 1044) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: severe, grade &gt; 2</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.92 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4546<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be explained by the involvement of low‐quality trials. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(196 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MAGE‐A3</b> : melanoma‐associated antigen 3: <b>NSCLC</b> : non‐small cell lung cancer; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence </b><br/>  </p> <p><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to methodological limitations: inclusion of data from low‐quality trials.<br/><sup>b</sup>Downgraded one level due to inconsistency: significant heterogeneity was detected during analysis. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011300-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011300-sec-0009"></div> <section id="CD011300-sec-0010"> <h3 class="title" id="CD011300-sec-0010">Description of the condition</h3> <p>Lung cancer is the most common cancer in men, and the leading cause of cancer‐related death worldwide (<a href="./references#CD011300-bbs2-0038" title="International Agency for Research on Cancer (IARC) . Cancer incidence and mortality worldwide. https://gco.iarc.fr/databases.php (accessed 8 November 2021).">GLOBOCAN 2020</a>). In 2020, there were an estimated 2.2 million new lung cancer cases (accounting for 11.4% of all new cancer cases), making up to 18% of total cancer deaths worldwide (<a href="./references#CD011300-bbs2-0038" title="International Agency for Research on Cancer (IARC) . Cancer incidence and mortality worldwide. https://gco.iarc.fr/databases.php (accessed 8 November 2021).">GLOBOCAN 2020</a>). Clinically, there are two main types of lung cancer: non‐small cell lung cancer (NSCLC), the most common type, accounting for approximately 80% to 85% of all lung cancer cases, and small cell lung cancer (SCLC; <a href="./references#CD011300-bbs2-0061" title="HerbstRS , HeymachJV , LippmanSM . Lung cancer. New England Journal of Medicine2008;359(13):1367-80.">Roy 2008</a>). This classification is important for deciding treatment and predicting prognosis (<a href="./references#CD011300-bbs2-0061" title="HerbstRS , HeymachJV , LippmanSM . Lung cancer. New England Journal of Medicine2008;359(13):1367-80.">Roy 2008</a>). Another key issue for clinical management is lung cancer staging ‐ the assessment of the extent of spread of cancer from its original source (<a href="./references#CD011300-bbs2-0031" title="DetterbeckFC , BoffaDJ , TanoueLT . The new lung cancer staging system. Chest2009;136(1):260-71.">Detterbeck 2009</a>). For NSCLC, the best outcomes are achieved with complete surgical resection of a stage IA tumour, with up to a 70% 5‐year survival rate (<a href="./references#CD011300-bbs2-0050" title="MountainCF . Revisions in the international system for staging lung cancer. Chest1997;111:1710–17.">Mountain 1997</a>). However, the corresponding rates for later stages drop sharply to less than 20% for stage IIIA; the worst survival is seen in stage IV patients, with 2% living longer than five years from diagnosis.  </p> <p>Despite the recent advances in the treatment of NSCLC, there has been little improvement in overall survival (<a href="./references#CD011300-bbs2-0051" title="National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. www.seer.cancer.gov/statfacts/html/lungb.html (accessed 14 November 2017).">National Cancer Institute 2017</a>). The current standard treatment is surgical resection (lobectomy and adequate mediastinal lymph node evaluation), with or without adjuvant chemotherapy, for those with early‐stage disease (<a href="./references#CD011300-bbs2-0044" title="HowingtonJA , BlumMG , ChangAC , BalekianAA , MurthySC . Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2013;143(5 Suppl):e278S-e313S.">Howington 2013</a>). For people with unresectable, locally advanced tumours (some stage IIIA and all stage IIIB patients), curative radiotherapy combined with chemotherapy is usually offered (<a href="./references#CD011300-bbs2-0058" title="RamnathN , DillingTJ , HarrisLJ , KimAW , MichaudGC , BalekianAA , et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2013;143(5 Suppl):e314S-e40S.">Ramnath 2013</a>). Although there is a chance of being cured, overall outcomes for people with stages I to III are not very good. Even after curative treatment, many patients develop a local or distant recurrence (<a href="./references#CD011300-bbs2-0047" title="LardinoisD , SuterH , HakkiH , RoussonV , BetticherD , RisHB . Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Annals of Thoracic Surgery2005;80(1):268-74.">Lardinois 2005</a>). We need more effective, and better tolerated therapeutic options, to prevent relapse and improve the rate of cure. Cancer immunotherapy is one possible approach. </p> </section> <section id="CD011300-sec-0011"> <h3 class="title" id="CD011300-sec-0011">Description of the intervention</h3> <p>'Cancer immunotherapy' generally refers to the use of a number of agents that activate or potentiate immune responses and increase anticancer immunity (<a href="./references#CD011300-bbs2-0049" title="MellmanI , CoukosG , DranoffG . Cancer immunotherapy comes of age. Nature2011;480(7378):480-9.">Mellman 2011</a>). Immunotherapy can be either active or passive. Active immunotherapy is treatment that stimulates the innate immune system to attack cancer cells (<a href="./references#CD011300-bbs2-0043" title="HirschowitzEA , HiestandDM , YannelliJR . Vaccines for lung cancer. Journal of Thoracic Oncology2006;1(1):93-104.">Hirschowitz 2006</a>). Antigen‐specific cancer immunotherapeutics (ASCIs) use exogenous antigens, ideally as tumour‐specific as possible, to induce the immune system to produce an effective T‐cell response against cancer cells (<a href="./references#CD011300-bbs2-0066" title="TyagiP , MirakhurB . MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clinical Lung Cancer2009;10(5):371-4.">Tyagi 2009</a>). A strong adjuvant component to stimulate the immune response and a proper delivery system for promoting antigen presentation are needed for ASCIs to be effective (<a href="./references#CD011300-bbs2-0049" title="MellmanI , CoukosG , DranoffG . Cancer immunotherapy comes of age. Nature2011;480(7378):480-9.">Mellman 2011</a>). Passive immunotherapy provides immune effector molecules or effector cells made outside of the human body to modulate immunity. These include monoclonal antibodies and adoptive cell transfer of autologous T‐cells genetically engineered to attack tumour cells.  </p> <p>Currently, immunotherapy has been used successfully in people with malignant melanoma and renal cell carcinoma, because of their high immunogenicity (<a href="./references#CD011300-bbs2-0033" title="DrakeCG , LipsonEJ , BrahmerJR . Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nature Reviews. Clinical Oncology2014;11(1):24-37.">Drake 2014</a>). Although there are suggestions that lung cancer is a highly immunogenic tumour, initial attempts to administer immunotherapy to people with NSCLC have failed to show clinical benefit (<a href="./references#CD011300-bbs2-0030" title="DasanuCA , SethiN , AhmedN . Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opinion on Biological Therapy2012;12(7):923-37.">Dasanu 2012</a>). However, significant improvements may come from newer agents, by identifying more relevant, targeted antigens, and developing better adjuvants and delivery systems (<a href="./references#CD011300-bbs2-0035" title="FinnOJ . Cancer immunology. New England Journal of Medicine2008;358(25):2704-15.">Finn 2008</a>; <a href="./references#CD011300-bbs2-0036" title="FordePM , KellyRJ , BrahmerJR . New strategies in lung cancer: translating immunotherapy into clinical practice. Clinical Cancer Research2014;20(5):1067-73.">Forde 2014</a>). Trial reports have recorded significant objective response rates using novel agents that block immune checkpoint molecules (<a href="./references#CD011300-bbs2-0065" title="TopalianSL , HodiFS , BrahmerJR , GettingerSN , SmithDC , McDermottDF , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine2012;366(26):2443-54.">Topalian 2012</a>). Also, with promising results from phase II trials, several new approaches have been tested in randomised phase III clinical trials, targeting different stages of NSCLC (<a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>). </p> </section> <section id="CD011300-sec-0012"> <h3 class="title" id="CD011300-sec-0012">How the intervention might work</h3> <p>The idea of cancer immunotherapy originated with the improved understanding of immune surveillance, a process by which the immune system can recognise malignant cells as foreign, and then induce immune responses to eliminate them (<a href="./references#CD011300-bbs2-0035" title="FinnOJ . Cancer immunology. New England Journal of Medicine2008;358(25):2704-15.">Finn 2008</a>). Physiologically, a normal cellular immune response starts with the uptake of tumour antigens by antigen‐presenting cells, such as dendritic cells or macrophages. Antigen‐presenting cells then process the antigens to T‐cells, by presenting them on their surfaces via major histocompatibility complex classes I and II. With assistance from co‐stimulatory signals, different downstream immune effectors (e.g. plasma cells, natural killer (NK) cells, and cytotoxic T‐cells) may be activated, consequently causing the apoptosis (death) of tumour cells (<a href="#CD011300-fig-0001">Figure 1</a>). However, immune surveillance may be limited by other factors. If there is an immunosuppressive microenvironment, even malignant tumour cells that carry unusual antigens can escape an immune‐mediated attack (<a href="./references#CD011300-bbs2-0032" title="DrakeCG , JaffeeE , PardollDM . Mechanisms of immune evasion by tumors. Advances in Immunology2006;90:51-81.">Drake 2006</a>). One such resistance mechanism involves a series of immune checkpoint molecules presenting on the cell surface, including programmed death‐ligand 1 (PD‐L1) and other ligands to inhibitory T‐cell receptors, which can substantially suppress T‐cell proliferation and its killing capacity (<a href="./references#CD011300-bbs2-0045" title="KeirME , ButteMJ , FreemanGJ , SharpeAH . PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology2008;26:677-704.">Keir 2008</a>).  </p> <div class="figure" id="CD011300-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Schematic diagram of the immune components and events involved in cancer immunotherapyAPCs: antigen‐presenting cells; MHC: major histocompatibility complex; NK: natural killer" data-id="CD011300-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic diagram of the immune components and events involved in cancer immunotherapy</p> <p>APCs: antigen‐presenting cells; MHC: major histocompatibility complex; NK: natural killer </p> </div> </div> </div> <p>Therapeutic cancer vaccination and monoclonal antibodies that block immune checkpoints are the most widely used immunotherapies for NSCLC treatment, especially for stages I to III. Our main focus for the review was the effect of therapeutic cancer vaccines, which can be summarised by the type of antigens described below. </p> <section id="CD011300-sec-0013"> <h4 class="title">Cell‐based vaccines</h4> <p>Autologous cell vaccines, generated from lysate or whole cells from the tumours of individual patients, have the advantage of stimulating an immune response in a large variety of tumour‐specific antigens expressed by the patient's cancer cells. In contrast, allogeneic cell vaccines use mixtures of different cancer cell lines. For instance, the belagenpumatucel‐L vaccine is composed of several lung cancer cell lines (2 adenocarcinomas, 1 squamous cell carcinoma, and 1 large cell carcinoma), and two adjuvants, which form a major histocompatibility complex and antisense molecule, targeting transforming growth factor ß2 (TGF‐ß2; <a href="./references#CD011300-bbs2-0037" title="GiacconeG , BazhenovaL , NemunaitisJ , JuhaszE , RamlauR , Van Den HeuvalMM , et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC). In: European Cancer Congress 2013. Amsterdam, 2013:Abstract n2.">Giaccone 2013</a>). Theoretically, expression of the TGF‐ß2 antisense molecule can undermine the TGF‐ß‐related immunosuppressive effect and potentiate dendritic cell activation, resulting in increased immunogenicity of gene‐modified cancer cells (<a href="./references#CD011300-bbs2-0056" title="NemunaitisJ , DillmanRO , SchwarzenbergerPO , SenzerN , CunninghamC , CutlerJ , et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. Journal of Clinical Oncology2006;24(29):4721-30.">Nemunaitis 2006</a>). More recently, NK cells have been developed as another type of cell vaccine. Modulated NK cells using soluble α‐galactosylceramide (α‐GalCer) in vivo was found to be tolerated, however there was no promising clinical response due to the low levels of baseline NK cells (<a href="./references#CD011300-bbs2-0040" title="Conall Hayes. Cellular immunotherapies for cancer. Irish Journal of Medical Science2021;190:41–57.">Hayes 2021</a>). Furthermore, a clinical trial using ex vivo Hsp70‐derived peptide (TKDNNLLGRFELSG, TKD)/interleukin‐2 (IL‐2)‐activated  autologous NK cells show it was well‐tolerated, with positive clinical responses (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>).  </p> </section> <section id="CD011300-sec-0014"> <h4 class="title">Compound‐directed vaccines</h4> <p>Peptide vaccines are based on amino acid sequences. However, since they can only target a few epitopes, their major shortcoming is poor immunogenicity (<a href="./references#CD011300-bbs2-0046" title="KochenderferJN , GressRE . A comparison and critical analysis of preclinical anticancer vaccination strategies. Experimental Biology and Medicine2007;232(9):1130-41.">Kochenderfer 2007</a>). This defect can be circumvented by incorporating an efficient delivery system or immunoadjuvants, such as the L‐BLP25 vaccine (known as stimuvax or tecemotide). The L‐BLP25 vaccine consists of a 25‐amino acid sequence from the glycoprotein mucin‐1 (MUC‐1) protein, along with an immunoadjuvant (monophosphoryl lipid A), and a liposomal delivery system (<a href="./references#CD011300-bbs2-0062" title="SanghaR , ButtsC . L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clinical Cancer Research2007;13(15 Pt 2):s4652-4.">Sangha 2007</a>). MUC‐1 is a highly glycosylated transmembrane protein found on the epithelial cell surface. In cancer cells, MUC‐1 was reported to be frequently overexpressed, with an abnormally glycosylated status (<a href="./references#CD011300-bbs2-0027" title="BafnaS , KaurS , BatraSK . Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene2010;29(20):2893–904.">Bafna 2010</a>). Cancer‐associated MUC‐1 can induce abnormal interactions between receptor tyrosine kinases and other cell surface receptors, which in turn lead to inappropriate activation of intracellular signalling pathways. These events then facilitate the growth, proliferation, and survival of cancer cells (<a href="./references#CD011300-bbs2-0024" title="AcresB , LimacherJM . MUC1 as a target antigen for cancer immunotherapy. Expert Review of Vaccines2005;4(4):493-502.">Acres 2005</a>; <a href="./references#CD011300-bbs2-0027" title="BafnaS , KaurS , BatraSK . Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene2010;29(20):2893–904.">Bafna 2010</a>). In preclinical trials, the L‐BLP25 vaccine induced a cellular immune response, characterised by T‐cell proliferation in response to MUC‐1.  </p> <p>Protein‐based vaccines can elicit an immune response targeting multiple epitopes, but efficient implementation requires that they are combined with immunoadjuvants. Melanoma‐associated antigen 3 (MAGE‐A3) is considered to be a highly exclusive tumour‐specific antigen, since normally it is only expressed in the testes and placenta, where it remains inaccessible to T‐cells because of the lack of major histocompatibility complex molecules to present the antigens (<a href="./references#CD011300-bbs2-0063" title="SimpsonAJ , CaballeroOL , JungbluthA , ChenYT , OldLJ . Cancer/testis antigens, gametogenesis and cancer. Nature Reviews2005;5(8):615-25.">Simpson 2005</a>). Therefore, the MAGE‐A3 vaccine is expected to be a well‐tolerated therapy with minimal side effects. In several types of cancer cells, MAGE‐A3 expression increases with tumour stage (<a href="./references#CD011300-bbs2-0067" title="Van den EyndeBJ , van derBruggenP . T cell defined tumor antigens. Current Opinion in Immunology1997;9(5):684-93.">Van den Eynde 1997</a>). MAGE‐A3 is detected in about 35% to 50% of NSCLC tumours (<a href="./references#CD011300-bbs2-0066" title="TyagiP , MirakhurB . MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clinical Lung Cancer2009;10(5):371-4.">Tyagi 2009</a>). </p> </section> <section id="CD011300-sec-0015"> <h4 class="title">Viral‐based vaccines</h4> <p>Finally, another way to produce cancer vaccines is to incorporate the target antigen into a viral backbone. One such vaccine, consisting of a modified Ankara virus, known as TG4010, has been developed to target MUC‐1 (<a href="./references#CD011300-bbs2-0046" title="KochenderferJN , GressRE . A comparison and critical analysis of preclinical anticancer vaccination strategies. Experimental Biology and Medicine2007;232(9):1130-41.">Kochenderfer 2007</a>). </p> </section> </section> <section id="CD011300-sec-0016"> <h3 class="title" id="CD011300-sec-0016">Why it is important to do this review</h3> <p>Although immunotherapy for NSCLC showed disappointing results in earlier trials, more promising evidence of its efficacy has emerged in the last decade. For people with localised NSCLC (stages I to III), immunotherapy has been used to reduce the postoperative recurrence rate or negative clinical outcomes of current chemoradiotherapy for unresectable tumours. While several agents have now entered phase III clinical trials, there is a need for a systematic review to address the question of the effectiveness and safety of immunotherapy in such patients. It is also unclear what the most effective type of immunotherapeutic agents is, and which group of patients could benefit most from this treatment. Therefore, our subgroup analysis might offer supportive evidence to optimise its further development and application in the clinic.  </p> <p>This review was first published in 2017, and updated in May 2021.</p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011300-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011300-sec-0017"></div> <p>To assess the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) among people with localised NSCLC of stages I to III who received curative intent of radiotherapy or surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011300-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011300-sec-0018"></div> <section id="CD011300-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011300-sec-0020"> <h4 class="title">Types of studies</h4> <p>We only included randomised controlled trials (RCTs).</p> </section> <section id="CD011300-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included all adults (18 years or older) with histologically‐confirmed early‐stage NSCLC (stages I to III) after surgical resection (with or without chemotherapy), and those with unresectable locally advanced stage III NSCLC who had received radiotherapy, or radiotherapy combined with chemotherapy with curative intent. </p> </section> <section id="CD011300-sec-0022"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD011300-list-0001"> <li> <p>Surgical treatment + immunotherapy agents versus surgical treatment with placebo, best supportive care, or no intervention. </p> </li> <li> <p>Radical radiotherapy (with or without chemotherapy) + immunotherapy agents versus radical radiotherapy (with or without chemotherapy) with placebo, best supportive care, or no intervention. </p> </li> </ul> </p> </section> <section id="CD011300-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD011300-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011300-list-0002"> <li> <p>Overall survival: defined as the interval between the date of randomisation and the date of death from any cause. </p> </li> <li> <p>Progression‐free survival: defined as the time from randomisation to either death or disease progression, whichever occurred first. Disease progression was defined according to response evaluation criteria in solid tumours (RECIST; <a href="./references#CD011300-bbs2-0064" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute2000;92(3):205-16.">Therasse 2000</a>), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since the treatment starts, or the appearance of one or more new lesions. </p> </li> </ul> </p> </section> <section id="CD011300-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011300-list-0003"> <li> <p>Overall survival rates: the percentage of participants in a study who were still alive for a certain period of time. </p> </li> <li> <p>Adverse events or side effects: graded severity with the National Cancer Institute‐Common Terminology Criteria for Adverse Events (<a href="./references#CD011300-bbs2-0052" title="National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf November 27, 2017.">NCI‐CTCAE 2017</a>), including the percentage of treatment‐related deaths. </p> </li> <li> <p>Overall response: response assessed according to RECIST guidelines (<a href="./references#CD011300-bbs2-0064" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute2000;92(3):205-16.">Therasse 2000</a>), or immune‐related response criteria (<a href="./references#CD011300-bbs2-0068" title="WolchokJD , HoosA , O'DayS , WeberJS , HamidO , LebbéC , et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research2009;15(23):7412-20.">Wolchok 2009</a>). </p> </li> <li> <p>Health‐related quality of life: measured by a validated scale.</p> </li> </ul> </p> <p>We included all primary outcomes, as well as parts of secondary outcomes in a summary of findings table (<a href="./full#CD011300-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> </section> <section id="CD011300-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011300-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We conducted a literature search to identify all published or unpublished RCTs. The literature search identified potential trials in all languages. </p> <p>We searched the following electronic databases for potential trials.</p> <p> <ul id="CD011300-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 5) in the Cochrane Library, searched 19 May 2021 (<a href="./appendices#CD011300-sec-0080">Appendix 1</a>). </p> </li> <li> <p>MEDLINE PubMed (1966 to 19 May 2021; <a href="./appendices#CD011300-sec-0081">Appendix 2</a>). </p> </li> <li> <p>Embase (1988 to 19 May 2021; <a href="./appendices#CD011300-sec-0082">Appendix 3</a>). </p> </li> <li> <p>CINAHL (1982 to 19 May 2021).</p> </li> </ul> </p> <p>The search string for MEDLINE was developed according to the Cochrane Highly Sensitive Search Strategy, sensitivity‐maximising version, as referenced in Chapter 6.4.11.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011300-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). We adapted the terms and the search strategies for CENTRAL, MEDLINE, and Embase to search CINAHL.  </p> </section> <section id="CD011300-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We searched Clinical Trial Registers (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>), databases of the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">who.int/clinical-trials-registry</a>), to identify information about ongoing trials. We searched all databases from their inception to 19 May 2021.  </p> <p>We checked reference lists of all included trials and related reviews for additional references. We asked experts in the field and manufacturers of relevant drugs to provide details of outstanding clinical trials and any relevant unpublished material. We also contacted authors of identified trials and asked them to identify other published and unpublished trials. </p> <p>We manually checked for potential trials in abstracts or reports from the following relevant conference proceedings (from 1990 to present): American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Cancer Conference Organisation (ECCO), and International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference. </p> <p>We searched for errata or retractions from eligible trials on <a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a> on 19 May 2021.  </p> </section> </section> <section id="CD011300-sec-0029"> <h3 class="title" id="CD011300-sec-0029">Data collection and analysis</h3> <section id="CD011300-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (YY and XW for this updated review, or OT and ET for the original review) independently screened titles and abstracts of all trials that we identified as a result of the search, and labelled them as 'retrieve' (eligible, potentially eligible, or unclear) or 'do not retrieve'. For the ones coded as 'retrieve', we then referred to their full‐text study reports or publication. Two review authors (HS, RL) independently screened the full‐text reports. The procedure of study identification for inclusion and exclusion was well documented by using standard screening forms. We resolved any disagreement through discussion, or consulted a third review author (CS). </p> <p>We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD011300-bbs2-0048" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100.">Liberati 2009</a>), and '<a href="./references#CD011300-sec-0093" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD011300-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which we tested on one study in the review. One review author (RL) extracted study characteristics from included trials. We extracted the following study characteristics. </p> <p> <ul id="CD011300-list-0005"> <li> <p>Methods: study design (for example, parallel or cross‐over design), number of study centres and location (country), total duration (for example, date of study, follow‐up period, early stopping of trial), method of randomisation (including imbalanced randomisation ratio), methods of allocation concealment, blinding </p> </li> <li> <p>Participants: N, age, gender, Eastern Co‐operative Oncology Group (ECOG) performance status, medical history, the severity of condition (stage), diagnostic criteria, inclusion criteria, exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, excluded medications</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported</p> </li> <li> <p>Notes: funding for trial, or any notable conflicts of interest of trial authors</p> </li> </ul> </p> <p>Two review authors (YY and XW for this updated review, HS and RL for the original review) independently extracted outcome data from the included trials. We noted in the '<a href="./references#CD011300-sec-0092" title="">Characteristics of included studies</a>' table if outcome data were reported in an unusable way. We resolved disagreements by consensus, or by involving a third review author (CS). One review author (RL) copied the data from the data collection form into the Review Manager file (<a href="./references#CD011300-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that the data were entered correctly by comparing the study reports with the data in the systematic review. A second review author (JZ) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD011300-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (YY and XW for this updated review, HS and RL for the original review) independently assessed the risk of bias for each study, using RoB 1 (<a href="./references#CD011300-bbs2-0041" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Any disagreements were resolved by discussion, or by involving a third assessor (JZ). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD011300-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential bias</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear, and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different trials for each of the domains listed. For overall risk of bias, we considered trials that had adequate random sequence generation, adequate allocation concealment, adequate blinding, adequate handling of incomplete outcome data, no selective outcome reporting, and were without other bias risks, as being at overall low risk of bias. We considered trials that were assessed as being at high or unclear risk of bias in the majority of domains as being at overall high risk of bias; and the remaining trials to be at low risk of bias. We considered blinding separately for different key outcomes where necessary e.g. for unblinded outcome assessment, the risk of bias for all‐cause mortality may be very different than for a participant‐reported pain scale. Where information on the risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the trials that contributed to that outcome. </p> </section> <section id="CD011300-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the primary outcomes based on intention‐to‐treat (ITT) analyses, where available. We measured effect estimates by hazard ratios (HRs) for time‐to‐event variables, and risk ratios (RRs) for dichotomous variables. For continuous variables, we calculated mean differences (MDs) with their corresponding 95% confidence intervals (CIs) if trials used the same measurement, and standardised mean differences (SMDs) and 95% CIs when trials use different scales. We contacted the corresponding authors for missing information about standard deviations or standard errors. For reports without available data for pooling, we tried to measure rates from figures, and calculated effect estimates from P values, t statistics, ANOVA tables, or other statistics as appropriate. </p> </section> <section id="CD011300-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>We did not find any trials with non‐standard design (such as cluster‐randomised trials for potential 'unit of analysis error') for this updated review. But if such eligible trials emerge in future literature searches, we will carefully assess these trials (in terms of recruitment bias, baseline imbalance, loss of clusters, and comparability with individually‐randomised trials). Furthermore, we will apply proper statistical methods (such as multilevel models and generalised estimating equations) for analysis, according to the <i>Handbook for Systematic Review of Interventions</i> (<a href="./references#CD011300-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). The individual participant was the unit of analysis for this updated review. </p> <p>If there had been data from a cross‐over trial with eligible intervention performances, we would have used the data from the first phase only, i.e. from randomisation to the point of cross‐over. </p> <p>Had multiple trial arms been reported in a single trial, we would only have included the relevant arms. In future, if we enter two comparisons (e.g. drug A versus placebo and drug B versus placebo) from the same trial into the same meta‐analysis, we will halve the control group to avoid double counting.<br/>  </p> </section> <section id="CD011300-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and obtain missing outcome data where applicable (e.g. when a study was identified as an abstract only). For full‐text reports with missing details relevant to our analysis, we also contacted the authors of the trials by email. In the case of non‐response after repeated attempts, we dropped these incomplete data from the analysis, stating this clearly in the <a href="./full#CD011300-sec-0043">Results</a> section, and discussed it further under the <a href="#CD011300-sec-0072">Potential biases in the review process</a> section of the <a href="#CD011300-sec-0068">Discussion</a>. </p> </section> <section id="CD011300-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We carried out tests for heterogeneity using the Chi² test, to assesses whether observed differences in results were compatible with chance alone. We used the I² statistic to quantify inconsistency across trials. The presence of heterogeneity was defined by P &lt; 0.05 from the Chi² test, and I² &gt; 50% (<a href="./references#CD011300-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). If we detected moderate or higher heterogeneity (50% to 100%), we applied a thorough exploration of possible sources of heterogeneity by means of subgroup and sensitivity analyses (as stated below). Given the limitations of the methods, the P value from the Chi² test and the value of I² were only referred to as a guide, and we exercised caution when interpreting the results. </p> </section> <section id="CD011300-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to contact study authors, asking them to provide missing outcome data. When this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such trials in the overall assessment of results by conducting a sensitivity analysis<b>.</b> </p> <p>We did not include sufficient trials for each outcome in the current updated review to create a funnel plot. But if we are able to pool more than 10 trials in future updates, we will do so to explore possible publication biases (intervention effect estimate versus standard error of intervention effect estimate). If we find funnel plot asymmetry, we will further investigate clinical diversity of trials as a possible explanation. If there are sufficient trials (&gt; 10), we also will use the 'contour‐enhanced' funnel plot to differentiate asymmetry due to other factors (<a href="./references#CD011300-bbs2-0057" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991–6.">Peters 2008</a>). If the supposed missing trials are in areas of higher statistical significance, the cause of the asymmetry is highly suggestive of being due to factors other than publication bias. </p> </section> <section id="CD011300-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 for pooling data and for statistical analysis (<a href="./references#CD011300-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used random‐effects models for primary analyses since the agents of interest had different mechanisms of action. In the future (since currently no subgroup analysis was successfully conducted), provided that the trials in some subgroups are found to be homogeneous (in terms of age, diagnostic subtype, intervention type, intervention duration), we will use both fixed‐effect and random‐effects models, and compare the results. In the absence of heterogeneity and significant reporting bias, these two models should yield the same results. In this case, we will report the results from the fixed‐effect model only. If the results are different, indicating significant heterogeneity, we will report the results from the random‐effects model only. </p> </section> <section id="CD011300-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to perform the following exploratory subgroup analyses on the primary outcomes, using Review Manager 5 (<a href="./references#CD011300-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p> <ul id="CD011300-list-0007"> <li> <p>Participants receiving immunotherapy who present with a different stage of NSCLC (stages I, II, or III). </p> </li> <li> <p>Participants receiving different types of immunotherapy.</p> </li> <li> <p>Participants with a specific biomarker: e.g. participants with a gene‐signature profile (MAGE‐A3‐positive). </p> </li> </ul> </p> <p>In the current updated review, we did not include sufficient trials for each population (subgroup) of interest to conduct subgroup analyses. In future updates, we will perform a subgroup analysis for primary outcomes when we have at least three trials for a subgroup. </p> <p>Considering the differences between subgroups, we will first examine them by visual inspection of their CIs; non‐overlapping CIs indicate a statistically significant difference in treatment effect between subgroups. Also, we will use the approach of <a href="./references#CD011300-bbs2-0028" title="BorensteinM , HedgesLV , HigginsJP , RothsteinHR . Introduction to meta-analysis (Statistics in Practice). Chichester: John Wiley &amp; Sons, 2008.">Borenstein 2008</a> to formally investigate differences between two or more subgroups. </p> </section> <section id="CD011300-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses, defined a priori, to assess the robustness of our conclusions. This was achieved by repeating the analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD011300-list-0008"> <li> <p>Exclusion of unpublished trials (in the current updated review, we did not include unpublished data, but will conduct this analysis if unpublished data are included in future updates). </p> </li> <li> <p>Exclusion of lower quality trials (those at high or unclear risk of bias).</p> </li> </ul> </p> </section> <section id="CD011300-sec-0041"> <h4 class="title">Summary of findings and assessment of the quality of the evidence</h4> <p>We created a summary of findings table presenting all our primary and secondary outcomes, except overall response and health‐related quality of life, using GRADEpro software (<a href="./references#CD011300-bbs2-0039" title="McMaster University (developed by Evidence Prime)GRADEpro. Version accessed prior to 1 November 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org.">GRADEpro GDT</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence as it related to the trials that contributed data to the meta‐analyses for the prespecified outcomes. We justified decisions to downgrade or upgrade the quality of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary (<a href="./references#CD011300-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD011300-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a 'Summary of findings' table presenting all our primary and secondary outcomes except overall response and health‐related quality of life, using the GRADEpro software, version 3.2 (<a href="./references#CD011300-bbs2-0039" title="McMaster University (developed by Evidence Prime)GRADEpro. Version accessed prior to 1 November 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org.">GRADEpro GDT</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence as it related to the studies that contributed data to the meta‐analyses for the pre‐specified outcomes. We justified decisions to downgrade or upgrade the quality of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011300-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011300-sec-0043"></div> <section id="CD011300-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD011300-sec-0045"> <h4 class="title">Results of the search</h4> <p><a href="#CD011300-fig-0002">Figure 2</a> shows details of the updated search results from 20/01/2017 to 19/05/2021. We identified 6218 citations in this updated version of the review (723 from CENTRAL, 3543 from MEDLINE, and 1952 from Embase). In addition, we found 3 ongoing trials in <a href="http://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (<a href="./references#CD011300-bbs2-0020" title="NCT00960115. Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy. www.clinicaltrials.gov/ct2/show/NCT00960115 (first received 17 August 2009). ">Merck 2015</a>; <a href="./references#CD011300-bbs2-0021" title="SakaH ,  KitagawaC ,  IchinoseY ,  TakenoyamaM ,  IbataH ,  KatoT ,  et al. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial. Trials2017;18:429. ">Saka 2017</a>; <a href="./references#CD011300-bbs2-0022" title="WuYL , ParkK , SooRA , SunY , TyrollerK , WagesD , et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer2011;11:430. ">Wu 2011</a>). We did not find any relevant abstract or trial from conference proceedings by handsearching.   </p> <div class="figure" id="CD011300-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD011300-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>We retained 5439 references after excluding duplicates. By screening the titles and abstracts, we excluded 5429 citations, including the protocol published by <a href="./references#CD011300-bbs2-0022" title="WuYL , ParkK , SooRA , SunY , TyrollerK , WagesD , et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer2011;11:430. ">Wu 2011</a> describing a potentially eligible trial which was terminated prematurely (16 September 2016 at <a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>). We therefore had 10 new records considered to be highly relevant to our review. Among the 10 full‐text accessed, we excluded 8 trials with reasons (see <a href="#CD011300-sec-0051">Excluded studies</a>). Two trials met our inclusion criteria (<a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>). Combined with the nine full‐text reports from the original published version of the review (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>), our update includes 11 trials. </p> </section> <section id="CD011300-sec-0046"> <h4 class="title">Included studies</h4> <p>Overall, we included 11 trials after carefully evaluating potentially eligible articles, corresponding to 12 individual RCTs, with a total of 5128 participants (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>). Two trials after 20 January 2017, were newly included in this updated review. We summarised the characteristics of the included trials in the '<a href="./references#CD011300-sec-0092" title="">Characteristics of included studies</a>' tables.  </p> <p>Unfortunately, we did not manage to extract any relevant results from <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>, a small trial containing 48 Bacillus Calmette‐Guérin (BCG)‐treated and 40 control subjects. This trial reported survival time by tumour stage (stage I, stage II, and stage III), without providing any detailed data on overall survival, or adverse events, which were described in a very general way, where only fever and transient malaise were mentioned, without grading the severity. Also, because of the poor study quality of <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>, especially the conflicting data reported in the paper (survival rates in abstract, full text, and figures were different from each other), we decided not to include the results of this study in our analysis. </p> <section id="CD011300-sec-0047"> <h5 class="title">Study design</h5> <p>Four trials were double‐blind RCTs (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). With the exception of <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>, where the details of blinding were unclear, the other six had an open‐label design (<a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>). We included four multicentre international trials (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>), enrolling participants from the USA, Europe, and Asia. Other trials recruited participants from China (<a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>), Germany (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>), Italy (<a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>), Japan (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>), or the USA (<a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>). </p> </section> <section id="CD011300-sec-0048"> <h5 class="title">Participants</h5> <p>All included trials enrolled participants with histologically‐confirmed NSCLC. Two trials enrolled participants with stages I to III NSCLC (<a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Three RCTs focused on stage I or II completely resected NSCLC (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>); two trials were conducted on participants with stage II or III NSCLC (<a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>); and the remaining four only included participants with locally advanced NSCLC (stage III; <a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>). <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a> and <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a> were separate phase II and phase III clinical trials on MAGE‐A3 immunotherapy, and they only included participants with MAGE‐A3‐positive NSCLC. Likewise, <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a> was a phase II trial, which included participants with unresectable, membrane‐bound forms of Hsp70 (mHsp70)‐positive NSCLC. As stated above, 11 eligible trials enrolled a total of 5128 participants; after we excluded the two trials without usable information on outcomes of interest (<a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>), the total number of participants that contributed to the analyses was 4863. The mean age of analysed participants was 61 years, with a range of 19 to 89 years; 75.1% of them were men<b> </b>(<a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a> did not report the number of men and women). </p> </section> <section id="CD011300-sec-0049"> <h5 class="title">Interventions</h5> <p>Three trials included participants with unresectable NSCLC, in two of which, participants were receiving chemoradiotherapy and randomly assigned to receive immunotherapy (L‐BLP25) or placebo (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>). In another trial, participants were randomly assigned to natural killer (NK) cell‐based immunotherapy along with chemoradiotherapy, or chemoradiotherapy alone (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>). All other included RCTs included participants with surgically‐treated NSCLC. Four RCTs compared the immunotherapy group to a control group of either placebo, best supportive care, or no intervention (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>); the other four trials allowed adjuvant chemotherapy (<a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>), or chemoradiotherapy (<a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>), for both experimental and control groups. It is noteworthy that the immunotherapy agents used in these trials differed over the years. Earlier trials mainly studied active immunotherapy, such as BCG injected into the intrapleural space (<a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>), or into the tumour (<a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>). The focus of research then gradually moved to passive immunotherapy, with adoptive cell transfer (transfer factor (TF); <a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>), tumour‐infiltrating lymphocytes (TIL; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>), dendritic cell/cytokine‐induced killer (DC/CIK; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>), and natural killer (NK) cells (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>). Most recently, antigen‐specific cancer vaccines (MAGE‐A3; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>) and L‐BLP25 (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>), were widely introduced and evaluated.  </p> </section> <section id="CD011300-sec-0050"> <h5 class="title">Outcome measures</h5> <p>Apart from <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>, the remaining trials reported overall survival time, although measured in different ways. <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a> reported survival time by tumour stage (stage I, stage II, and stage III); but they only provided survival probability curves for stage I and stage III. Therefore, we could not extract any survival outcome data from this study. Only the four recent trials measured the difference in survival between experimental and control groups by time‐to‐event analysis and hazard ratio (HR; (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). <a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a> reported 5‐year and 10‐year survival rates and all other RCTs reported survival by a median or mean survival with ranges or standard deviation (SD). To enable the use of these data for meta‐analysis, we extracted data for 1‐year, 2‐year, 3‐year, and 5‐year survival rates from all included trials (where possible), from either text statements or survival curves, as secondary outcomes. <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a> reported progression‐free survival as the primary outcome. We extracted progression‐free survival data, as HRs, from five RCTs (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>).  </p> <p>The overall response was reported in only one RCT (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>). Adverse events were mentioned in eight trials, but we only included data from six of them in the analysis of adverse events (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>), since <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a> and <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a> reported adverse events in general, without grading the severity. Quality of life was reported in two RCTs (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>), assessed by the European Organisation for Reasearch and Treatment of Cancer (EORTC) Quality of Life Questionnaire‐Core 30 (QLQ‐C30)  (<a href="./references#CD011300-bbs2-0023" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365-76. [PMID: 8433390]">Aaronson 1993</a>) and EuroQoL‐5D (EQ‐5D)(<a href="./references#CD011300-bbs2-0034" title="EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990 Dec;16(3):199-208. [PMID: 10109801]">EuroQol 1990</a>) questionnaire, respectively. </p> <p>Because of the inconsistencies in the duration of follow‐up in the different trials, these point estimates should be interpreted with caution.  </p> </section> </section> <section id="CD011300-sec-0051"> <h4 class="title">Excluded studies</h4> <p>Please see <a href="./references#CD011300-sec-0093" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011300-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>In <a href="#CD011300-fig-0003">Figure 3</a> and <a href="#CD011300-fig-0004">Figure 4</a>, we summarised the risk of bias in the included trials. Overall, we considered three trials to be well‐designed and well‐conducted, and therefore we assessed these trials at low risk of bias (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). However, for all of them, the involvement of the sponsors during study design, analysis, and results interpretation was mentioned in their reports. One trial had unclear risks of bias for two domains of assessment, owing to limited study information for risk assessment reported in the published paper, and we considered this trial to have a unclear risk of bias (<a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>). The other seven trials were at high risk of bias, mainly because of non‐blinding design (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>).  </p> <div class="figure" id="CD011300-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias domain, presented as percentages across all included trials." data-id="CD011300-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias domain, presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD011300-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias domain, for each included trial." data-id="CD011300-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias domain, for each included trial. </p> </div> </div> </div> <section id="CD011300-sec-0053"> <h4 class="title">Allocation</h4> <p>Four trials described how they carried out the randomisation procedure in detail (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). The other trials did not provide details on how they randomised the participants into different treatment arms, so we considered them to be at unclear risk of selection bias (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>). For <a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>, <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>, <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>, and <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>, randomisation was done centrally, via the Internet, minimising the risk of lack of allocation concealment. <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a> randomised with a printed table of random numbers, which was concealed from investigators with a sealed envelope. </p> </section> <section id="CD011300-sec-0054"> <h4 class="title">Blinding</h4> <p>We judged the three trials with a double‐blind, placebo‐controlled design to be at low risk of bias for blinding of participants and researchers, as well as blinding of outcome assessors (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a> had a placebo comparator, but did not provide a detailed explanation of blinding of participants, so we evaluated it to be at unclear risk. We considered six trials to be at high risk of performance bias because they had no placebo comparator (open‐label design; (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>)).  </p> <p>To assess the influence of detection bias, we considered the concept of each outcome; we classified overall survival, yearly survival rates, and severe adverse events as objective effects of treatment, and so they are unlikely to be affected by the non‐blinding of outcome assessment. But progression‐free survival, response, quality of life, and less severe adverse events are subjective outcomes, and could be affected by the outcome assessors’ knowledge of treatment and the participant's awareness of the assignment status. We assessed all trials to be at low risk of detection bias for objective outcomes. For subjective outcomes, the risk of detection bias was low, when data were extracted with masking for assessors (progression‐free survival and any adverse event in <a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>, <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>, and <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>, and quality life in <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). And the risk of detection bias for subjective outcomes was high in the open‐label trial (progression‐free survival, overall response, and quality of life in <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>), and unclear in the trial with blinding of the outcome assessor not specified (progression‐free survival, quality of life, and any adverse events in <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>).  </p> </section> <section id="CD011300-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We considered all the included trials to be at low risk of bias, either because the number of participants missing from follow‐up was very low (dropout rates below 5%), or because the primary survival analysis was done on the intention‐to‐treat population of all participants randomly allocated to treatment. </p> </section> <section id="CD011300-sec-0056"> <h4 class="title">Selective reporting</h4> <p>The protocols of five trials were available, where all their prespecified (primary and secondary) outcomes were described in detail (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Since the pre‐published protocols were consistent with their reports, we judged these five trials to be at low risk of selective outcome reporting. We considered all other trials to be at high risk for selective reporting bias, because their study protocol was unavailable and they just reported part of the primary outcomes (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>). Only <a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>, <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>, <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>, and <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a> reported overall survival, together with progression‐free survival. Others reported overall survival, but in different formats (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a>). <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a> reported progression‐free survival as the primary outcome and did not report overall survival.  </p> </section> <section id="CD011300-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a> reported conflicting data in their paper (survival rates in abstract, full text, and figures were different from each other), and so we considered this study to be at high risk of other potential bias. For the remaining trials, since there was no obvious potential source of bias, we classified them to be at low risk of other potential biases.  </p> <p>However, four trials were funded by pharmaceutical companies (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>), and the sponsors played critical roles in study design, data collection, management and statistical analysis. Therefore, we carefully compared the final reports with their previously published protocols. The consistency between these two documents mitigated this concern, by indicating that in spite of the sponsors’ involvement, these trials were conducted as planned, and with full supervision by independent administrators.  </p> <p>The other seven RCTs had no connection with these companies and confirmed their independence in the study implementation.  </p> </section> </section> <section id="CD011300-sec-0058"> <h3 class="title" id="CD011300-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD011300-tbl-0001"><b>Summary of findings 1</b> Immunotherapy for surgically‐treated patients with non‐small cell lung cancer (NSCLC), with or without radiotherapy with curative intent</a> </p> <section id="CD011300-sec-0059"> <h4 class="title">Primary outcomes</h4> <section id="CD011300-sec-0060"> <h5 class="title">Effect of immunotherapy on overall survival for participants with stages I to III NSCLC </h5> <p>To enable the maximum use of eligible data for the meta‐analysis of survival outcomes, we used two approaches to pool data, the first examined overall survival, and the second examined overall survival rates during different time slots. We have provided details of the second analyses under <a href="#CD011300-sec-0025">Secondary outcomes</a>.  </p> <p>We extracted hazard ratios (HRs) from four trials (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). In total, 4179 participants were involved in these trials, and 3848 of them were evaluated for overall survival (92% of all randomised participants). Using a random‐effects model, the pooled results illustrated that the study groups did not have a reduced risk of death compared to the control groups (HR 0.94, 95% confidence interval (CI) 0.84 to 1.05; high‐quality evidence; <a href="./references#CD011300-fig-0007" title="">Analysis 1.1</a>; <a href="#CD011300-fig-0005">Figure 5</a>); we did not detect heterogeneity across the trials (I² = 0%; P = 0.56). Since only three out of the four included trials were considered to be at low risk of bias, we performed sensitivity analysis after excluding <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>. Results were consistent with the main analysis (HR 0.94, 95% CI 0.84 to 1.05) and we did not observe heterogeneity (I² = 2%; P = 0.36).  </p> <div class="figure" id="CD011300-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Overall survival." data-id="CD011300-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Overall survival. </p> </div> </div> </div> </section> <section id="CD011300-sec-0061"> <h5 class="title">Effect of immunotherapy on progression‐free survival for participants with stages I to III NSCLC </h5> <p>Five trials reported progression‐free survival (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Although different agents were used in these trials, we found no heterogeneity between the results of these five trials (I² = 0%; P = 0.49); using a random‐effects model, we found that immunotherapy plus surgery showed no advantage compared to surgery alone (HR 0.94, 95% CI 0.86 to 1.03; P = 0.19; moderate‐quality evidence; <a href="./full#CD011300-tbl-0001">summary of findings Table 1</a>; <a href="./references#CD011300-fig-0008" title="">Analysis 1.2</a>; <a href="#CD011300-fig-0006">Figure 6</a>). We performed a further sensitivity analysis after we excluded two moderate‐/low‐quality trials (<a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>). Similar to the main analysis, we did not observe heterogeneity (I² = 39%; P = 0.19), and we did not find a difference for progression‐free survival between the two arms (HR 0.93, 95% CI 0.81 to 1.07; moderate‐quality evidence). </p> <div class="figure" id="CD011300-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Progression‐free survival." data-id="CD011300-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Progression‐free survival. </p> </div> </div> </div> </section> </section> <section id="CD011300-sec-0062"> <h4 class="title">Secondary outcomes</h4> <section id="CD011300-sec-0063"> <h5 class="title">Effect of immunotherapy on overall survival rates for participants with stages I to III NSCLC </h5> <p>We added this outcome after assessing the data to capture as much information as we could on participant survival. We extracted 1‐year, 2‐year, and 3‐year survival rates from seven trials with 4420 participants (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0003" title="GiovanniBR , PaoloZ , SandroM , PaoloM , RiccardoA , GiovanniF , et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer1996;78(2):244-51. ">Giovanni 1996</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). The results from a random‐effects model showed no clear difference in 1‐year survival probabilities for participants treated with immunotherapy compared to participants assigned to control groups (risk ratio (RR) 1.02, 95% CI 0.96 to 1.08; <a href="./references#CD011300-fig-0009" title="">Analysis 1.3</a>). The RRs were similar for 2‐year (1.02, 95% CI 0.93 to 1.12; <a href="./references#CD011300-fig-0010" title="">Analysis 1.4</a>) and 3‐year survival probability (0.99, 95% CI 0.90 to 1.09; <a href="./references#CD011300-fig-0011" title="">Analysis 1.5</a>). There was moderate heterogeneity for 1‐year (I² = 57%; P = 0.03) and 2‐year (I² = 51%; P = 0.06) survival rates; while 3‐year survival rates showed low between‐trial heterogeneity (I² = 22%; P = 0.26). Five‐year survival rates were available from seven trials that included 2834 participants from the experimental and 1555 participants from the control groups<b>(</b><a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>;<b> </b><a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>;<b> </b><a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>;<b> </b><a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>;<b> </b><a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>;<b> </b><a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Analysis showed there was no clear benefit for 5‐year survival by adding immunotherapy (RR 0.98, 95% CI 0.86 to 1.12; <a href="./references#CD011300-fig-0012" title="">Analysis 1.6</a>), and there was no heterogeneity (I² = 0%; P = 0.75). We concluded that the quality of evidence for the 1‐year survival rate was low, primarily due to the inconsistency of effect across the trials and the involvement of trials with unclear or high risks of bias; the quality of evidence for 2‐year, 3‐year and 5‐year survival rates was moderate, because of the involvement of trials with high or unclear risk of selection bias.  </p> <p>Because of significant heterogeneity for the 1‐year survival rate, we repeated the analyses, restricting it to trials at low risk of bias. This sensitivity analysis suggested that the heterogeneity for 1‐year survival rates could be partly explained by the differences in study quality. And the inconsistency of effect size also was mitigated after the exclusion of low‐quality trials.  </p> </section> <section id="CD011300-sec-0064"> <h5 class="title">Effect of immunotherapy on adverse events for participants with stages I to III NSCLC</h5> <p>Four trials, with a total of 4126 evaluated participants, provided data on the proportion of participants with any adverse event, graded for severity (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Using a random‐effects model, our analysis showed that the addition of immunotherapy to surgery or curative radiotherapy lead to a similar risk of experiencing any adverse events among these participants (RR 1.12, 95% CI 0.97 to 1.28; P = 0.11; <a href="./references#CD011300-fig-0013" title="">Analysis 1.7</a>). The effect size varied substantially between trials (suggesting a drug‐specific effect on this outcome), which corresponded to a high level of heterogeneity between individual outcomes (I² = 95%; P &lt; 0.00001). We also observed an increase in the general adverse event risk (RR 1.23, 95% CI 1.18 to 1.29; I² = 0%; P &lt; 0.00001) by restricting the analysis to MAGE‐A3 trials (<a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>).  </p> <p>Six trials (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>), with 2979 evaluated participants in the experimental and 1567 evaluated participants in the control groups, showed that participants receiving immunotherapy did not have different risk of severe adverse events (severity grade &gt; 2) than their controls (RR 1.14, 95% CI 0.92 to 1.40; <a href="./references#CD011300-fig-0014" title="">Analysis 1.8</a>). We also found moderate heterogeneity among the results of these trials (I² = 56%; P = 0.04). Moreover, heterogeneity disappeared in the following sensitivity analysis where low‐quality trials were removed (RR 0.96, 95% CI 0.86 to 1.08; I² = 0%; P = 0.72), indicating that the inconsistency might have originated from the inclusion of two high risk of bias trials (<a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>), and one unclear risk of bias trial (<a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>). In summary, we considered there was low‐quality evidence for both any adverse event, and severe adverse events (due to the involvement of low‐quality trials and significant heterogeneity; <a href="./full#CD011300-tbl-0001">summary of findings Table 1</a>).  </p> </section> <section id="CD011300-sec-0065"> <h5 class="title">Effect of immunotherapy on overall response rate for participants with stages I to III NSCLC </h5> <p>The overall response was assessed only in <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a> according to RECIST guidelines (<a href="./references#CD011300-bbs2-0064" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute2000;92(3):205-16.">Therasse 2000</a>). One participant in the experimental group showed complete response, and one participant showed partial response. One participant in the control arm had a partial response. The overall response rate was 33% (2/6) in the experimental group and 14% (1/7) in the control group.  </p> </section> <section id="CD011300-sec-0066"> <h5 class="title">Effect of immunotherapy on health‐related quality of life for participants with stages I to III NSCLC </h5> <p><a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a> assessed the health‐related quality of life of their participants (1515 experimental and 757 control), using both EQ‐5D (<a href="./references#CD011300-bbs2-0034" title="EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990 Dec;16(3):199-208. [PMID: 10109801]">EuroQol 1990</a>) utility scores and visual analogue scores (VAS) (<a href="./references#CD011300-bbs2-0025" title="AitkenRC . Measurement of feelings using visual analogue scales. Proceedings of the Royal Society of Medicine1969;62(10):989–93. [PMID: 4899510]">Aitken 1969</a>). They did not find any evidence that the application of melanoma‐associated antigen 3 (MAGE‐A3) improved quality of life. Instead, the immunotherapy group reported significantly lower scores (indicating poorer life quality) on quality of life assessments on the day after the first and the third MAGE‐A3 administrations, compared to the control group.  </p> <p><a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a> assessed the quality of life of participants using the QLQ‐C30 (<a href="./references#CD011300-bbs2-0023" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365-76. [PMID: 8433390]">Aaronson 1993</a>). Differences in means of sum scores of the QLQ‐C30 varied at multiple visits, and the experimental group, in general, had a better quality of life during the follow‐up period. However, there were no differences between both studied groups across all visits.  </p> </section> </section> <section id="CD011300-sec-0067"> <h4 class="title">Subgroup analysis</h4> <p>As described in our protocol, we had planned to perform subgroup analysis for primary outcomes according to participants at different tumour stages (I, II, or III), type of immunotherapy, and specific prognostic biomarkers that were used for participant selection. However, since we only found four trials with data for primary outcome analyses, we were not able to conduct any subgroup analyses at this stage.  </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011300-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011300-sec-0068"></div> <section id="CD011300-sec-0069"> <h3 class="title" id="CD011300-sec-0069">Summary of main results</h3> <p>This updated review, which pooled survival data from trials that focused mainly on vaccine‐based immunotherapy, showed that there was no clear evidence of additional survival benefit from immunotherapy (excluding checkpoint inhibitors) for people with stages I to III NSCLC, who had undergone surgery or received radiotherapy with curative intent. For overall survival, pooled data from four (3848 participants analysed) of the 11 included trials suggested no difference in death (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84 to 1.05) for those receiving immunotherapy, compared to their controls. Moreover, the pooled data from five (3861 participants analysed) of the 11 included trials also indicated a similar result in risk of progression (progression‐free survival HR 0.94, 95% CI 0.86 to 1.03) for those receiving immunotherapy. Similarly, survival rate analyses of data from seven trials (4420 participants) showed no improvement of 1‐year, 2‐year, 3‐year, or 5‐year survival associated with the addition of immunotherapy agents. Sensitivity analysis showed that the exclusion of low‐quality data could not explain the observed variation in study results. Due to the small number of trials, we could not perform subgroup analyses to detect the possible differences caused by tumour stage, type of immunotherapy, or the use of a specific prognostic biomarker. </p> <p>Furthermore, we observed similar risk of experiencing any adverse event (12% for MAGE‐A3 and L‐BLP25 together (P = 0.11)) for participants who were assigned to immunotherapy, compared to the control groups. The risk of having severe adverse events also showed no clear increase (RR 1.14, 95% CI 0.92 to 1.40).  </p> <p>Two of the 11 included trials reported controversial findings about quality of life after immunotherapy. The immunotherapy group in the MAGE‐A3 study reported significantly lower scores (indicating poorer life quality) on quality of life assessments on the day after the first and the third MAGE‐A3 administrations, however the experimental group of the NK cell study showed a better quality of life during the follow‐up period, compared to their controls. The immunotherapy group in one study reported significantly higher overall response rate, indicating better therapy response, compared with the control group. </p> </section> <section id="CD011300-sec-0070"> <h3 class="title" id="CD011300-sec-0070">Overall completeness and applicability of evidence</h3> <p>In order to reduce publication bias, our literature search sought unpublished or ongoing trials, without any limitation on publication language. However, the identified trials only partially addressed the objectives of the review, mainly because data about the effect of immunotherapy for participants with stages I to III NSCLC were insufficiently described. Survival outcomes were reported in various ways. Only five recent trials (45% of included trials) provided adequate data for overall survival and progression‐free survival (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Due to the absence of a uniform approach for group comparison, data extraction and analyses from earlier trials was difficult. In addition, because of clinical (different agents used in each trial, and participants with different tumour stages) and statistical heterogeneity, the legitimacy of pooling results may be debatable. The limited number of included trials prevented us from detailed comparisons within more homogeneous subgroups. Also, some important outcomes, such as response rates and health‐related quality of life, could not be examined in this updated review, since response rates were only measured in one trial and quality of life from two trials was measured on different scales.  </p> <p>At the time of our literature search, new immunotherapy agents, i.e. checkpoint inhibitors (PD‐1/PD‐L1), are mainly applied to people with either advanced stage or metastatic NSCLC. Several trials that aimed to assess the efficacy and safety of checkpoint inhibitor drugs are still ongoing (<a href="./references#CD011300-bbs2-0053" title="NCT02273375. A phase III prospective double-blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT02273375.">NCT02273375</a>; <a href="./references#CD011300-bbs2-0054" title="NCT02486718. Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer [IMpower010]. https://clinicaltrials.gov/ct2/show/NCT02486718.">NCT02486718</a>; <a href="./references#CD011300-bbs2-0055" title="NCT02504372. Study of pembrolizumab (MK-3475) vs placebo for participants with non-small cell lung cancer after resection with or without standard adjuvant therapy (MK-3475-091/KEYNOTE-091) (PEARLS). https://clinicaltrials.gov/ct2/show/NCT02504372.">NCT02504372</a>). Therefore, further reviews that focus on the effectiveness of checkpoint inhibitors for people with stage I to III NSCLC will be needed when results from several trials are available.  </p> </section> <section id="CD011300-sec-0071"> <h3 class="title" id="CD011300-sec-0071">Quality of the evidence</h3> <p>We identified 11 eligible RCTs. We could not extract useful data (for our outcomes of interest) from <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>, and we discarded results from <a href="./references#CD011300-bbs2-0011" title="ZhaoM , LiH , LiL , ZhangY . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Experimental and Therapeutic Medicine2014;7(5):1403-7. ">Zhao 2014</a> because of poor study quality and contradictory reports of the primary outcomes, leaving only nine trials for further analysis. Data from trials performed before 2000 generally were of poor quality, because of the open‐label design and lack of information provided about randomisation methods (particularly allocation concealment). We considered the four newer double‐blinded RCTs to be of high or moderate quality (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>).   </p> <p>It should be noted that the available data for the meta‐analyses of primary outcomes was incomplete. All participants included in the final analysis were from either four or five trials, and evaluated three types of immunotherapies, although we did not downgrade the quality of the evidence because of this. Clinical and statistical heterogeneity leads to a problem of imprecision for most of our outcomes of interest. We found no suggestion of publication bias, and therefore, no serious limitation was assumed. In addition, we could not explain the inconsistency between individual trial results by our predefined subgroups. </p> </section> <section id="CD011300-sec-0072"> <h3 class="title" id="CD011300-sec-0072">Potential biases in the review process</h3> <p>For the primary analyses, we combined all intervention groups' data, regardless of the type of immunotherapeutic agents administered, and the specific biomarker used for participant selection. Consequently, our analyses were subject to high potential risk of between‐study heterogeneity, due to clinical diversity. Further, we observed significant statistical heterogeneity in the analysis of the 1‐year survival rate. But, because only a limited number of eligible trials was included in these analyses, we were not able to fully explore the reasons for the variation by subgroup or sensitivity analysis. The unexplained inconsistency between individual trial results may undermine the reliability of our effectiveness assessment. </p> <p>Another issue relevant to the potential bias of our pooled results was the small proportion of trials included in the meta‐analyses of overall survival (36%) and progression‐free survival (45%), our primary outcomes (i.e. a large proportion of included trials were at high risk of selective reporting bias). Although these five trials contained more than 80% of all participants (4195/5128) from all eligible trials, such analyses were deemed to be incomplete, with over‐representation of the effects of most recent agents (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0004" title="KatakamiN , HidaT , NokiharaH , ImamuraF , SakaiH , AtagiS , et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer2017;105:23-30. ">Katakami 2017</a>; <a href="./references#CD011300-bbs2-0007" title="MulthoffG ,  SeierS ,  StanglS ,  SievertW ,  ShevtsovM ,  WernerC ,  et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clinical Trials: Immunotherapy2020;26:5368-79. ">Multhoff 2020</a>; <a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). This naturally limited our analysis to antigen‐specific vaccines (MAGE‐A3 and L‐BLP25) and cell‐based vaccines (NK cells). On the other hand, since other trials (with smaller numbers of participants) produced mixed results, we were unable to assess the efficacy of other types of immunotherapeutic agents in the current updated review.  </p> <p>Two review authors independently carried out study selection, assessment of risks of bias, and data collection, without blinding. Regarding missing data and missing information related to study quality assessment, we tried to contact authors by email to obtain these details. However, even after repeated attempts, we did not receive any response from these authors (since these trials were conducted a long time ago, the non‐response rates were expected to be high). In the end, we were unable to access sufficient information to assess the eligibility of two trials (Macchiarini 1989; Schlieben 1984). For the other trials, we deemed that there were unclear risks of certain study bias (see <a href="#CD011300-fig-0004">Figure 4</a>), and we extracted and used available data for the meta‐analysis for each outcome. Again, this could influence the accuracy and reliability of our results because of incomplete study assessment and data pooling.  </p> </section> <section id="CD011300-sec-0073"> <h3 class="title" id="CD011300-sec-0073">Agreements and disagreements with other studies or reviews</h3> <p>The survival benefit of immunotherapy for people with localised NSCLC has been discussed for decades. For early (stage I and II) or locally advanced (IIIA) NSCLC, the first attempts to use immunotherapy (mainly cellular immunity‐based therapeutic strategies) in such patients began in the 1980s, using active immunotherapy agents (e.g. Bacillus Calmette‐Guérin (BCG)) or adoptive cell transfer (e.g. transfer factor (TF)). Striking improvements in survival were observed in some clinical trials, including both RCTs (<a href="./references#CD011300-bbs2-0002" title="FujisawaT , YamaguchiY . Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma. Cancer1996;78(9):1892-8. ">Fujisawa 1996</a>; <a href="./references#CD011300-bbs2-0005" title="MacchiariniP , HardinM , AngelettiCA . Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer. American Journal of Clinical Oncology1991;14(4):291-7. ">Macchiarini 1991</a>), and non‐randomised clinical trials; while null results were reported in <a href="./references#CD011300-bbs2-0006" title="MatthayRA , MahlerDA , BeckGJ , LokeJ , BaueAE , CarterDC , et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Research1986;46(11):5963-8. ">Matthay 1986</a>. These attempts were finally thought to fail since the largest RCT (with 441 participants) found no significant difference between experimental and control groups (<a href="./references#CD011300-bbs2-0008" title="StanleyK , Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer1986;58(11):2411-6. ">Stanley 1986</a>). New efforts were launched after 2000, mainly applying vaccine‐based immunotherapy agents. Promising outcomes from small trials inspired further explorations (<a href="./references#CD011300-bbs2-0009" title="VansteenkisteJ , ZielinskiM , LinderA , DahabrehJ , GonzalezEE , MalinowskiW , et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Journal of Clinical Oncology2013;31(19):2396-403. ">Vansteenkiste 2013</a>). However, disappointing results were reported from later phase III RCTs (<a href="./references#CD011300-bbs2-0001" title="ButtsC , SocinskiMA , MitchellPL , ThatcherN , HavelL , KrzakowskiM , et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial. Lancet Oncolology2014;15(1):59-68. ">Butts 2014</a>; <a href="./references#CD011300-bbs2-0010" title="VansteenkisteJF , ChoBC , VanakesaT , dePasT , ZielinskiM , KimMS , et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2016;17(6):822-35. ">Vansteenkiste 2016</a>). Similar conclusions were drawn from other published reviews (<a href="./references#CD011300-bbs2-0029" title="CarrizosaDR , GoldKA . New strategies in immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research2015;4(5):553-9.">Carrizosa 2015</a>; <a href="./references#CD011300-bbs2-0059" title="ReckampKL . Advances in immunotherapy for non-small cell lung cancer. Clinical Advances in Hematology &amp; Oncology2015;13(12):847-53.">Reckamp 2015</a>). Nevertheless, new trials in this area have been started, with a focus on novel agents, especially immune checkpoint inhibitors, for which superior progression‐free survival has been reported in the planned interim analysis of one phase III RCT trial (<a href="./references#CD011300-bbs2-0026" title="AntoniaSJ ,  VillegasA ,  DanielD ,  VicenteD ,  MurakamiS ,  HuiR ,  et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New England Journal of Medicine2017;377(20):1919-29. [PMID: 28885881]">Antonia 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011300-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Schematic diagram of the immune components and events involved in cancer immunotherapyAPCs: antigen‐presenting cells; MHC: major histocompatibility complex; NK: natural killer" data-id="CD011300-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Schematic diagram of the immune components and events involved in cancer immunotherapy</p> <p>APCs: antigen‐presenting cells; MHC: major histocompatibility complex; NK: natural killer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011300-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias domain, presented as percentages across all included trials." data-id="CD011300-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias domain, presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias domain, for each included trial." data-id="CD011300-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias domain, for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Overall survival." data-id="CD011300-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Progression‐free survival." data-id="CD011300-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: Effect of immunotherapy for surgically‐treated NSCLC patients: main analyses, outcome: Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 1: Overall survival" data-id="CD011300-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 2: Progression‐free survival" data-id="CD011300-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 3: Overall survival rate, 1‐year" data-id="CD011300-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 3: Overall survival rate, 1‐year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 4: Overall survival rate, 2‐year" data-id="CD011300-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 4: Overall survival rate, 2‐year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 5: Overall survival rate, 3‐year" data-id="CD011300-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 5: Overall survival rate, 3‐year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 6: Overall survival rate, 5‐year" data-id="CD011300-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 6: Overall survival rate, 5‐year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 7: Adverse events (any)" data-id="CD011300-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 7: Adverse events (any) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011300-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/urn:x-wiley:14651858:media:CD011300:CD011300-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 8: Adverse events (severe, grade &gt; 2)" data-id="CD011300-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_t/tCD011300-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Effect of immunotherapy for surgically treated NSCLC patients: main analyses, Outcome 8: Adverse events (severe, grade &gt; 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/media/CDSR/CD011300/image_n/nCD011300-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011300-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immunotherapy for surgically‐treated patients with non‐small cell lung cancer (NSCLC), with or without radiotherapy with curative intent</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Immunotherapy for surgically‐treated NSCLC patients, with or without radiotherapy with curative intent</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> immunotherapy plus surgery (adjuvant chemotherapy or chemoradiotherapy was allowed, provided it was applied to both experimental and control groups)<br/><b>Comparison:</b> surgical treatment with placebo, best supportive care, no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with surgical treatment only (control group)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with immunotherapy plus surgery (experimental group)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median overall survival time ranged across control groups from 22.3 to 60.2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median overall survival time ranged across experimental groups from 25.6 to 62.0 months </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.84 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3848</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median progression‐free survival time ranged across control groups from 11.4 to 57.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median progression‐free survival time ranged across experimental groups from 14.2 to 60.5 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.86 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3861<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 1‐year survival rate</p> <p> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.96 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be partly explained by the inclusion of data from trials with high risk of bias. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>824 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>841 per 1000<br/>(792 to 891) </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 2‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.93 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000 (551 to 664)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 3‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.90 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(333 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival: 5‐year survival rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.86 to 1.12) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4389<br/>(7 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(71 to 92) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: any</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.97 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4126<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup><br/>  </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be explained by the different agents applied in different trials. By restricting to MAGE‐A3 trials, we observed statistically significant elevation in general adverse event risk (RR 1.23, 95% CI 1.18 to 1.29; I² = 0%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>805 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>913 per 1000<br/>(791 to 1044) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: severe, grade &gt; 2</p> <p>(Duration of follow‐up varied between trials: median follow‐up time ranged from 37.7 months to 70 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.92 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4546<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The presence of heterogeneity could be explained by the involvement of low‐quality trials. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(196 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MAGE‐A3</b> : melanoma‐associated antigen 3: <b>NSCLC</b> : non‐small cell lung cancer; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence </b><br/>  </p> <p><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to methodological limitations: inclusion of data from low‐quality trials.<br/><sup>b</sup>Downgraded one level due to inconsistency: significant heterogeneity was detected during analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immunotherapy for surgically‐treated patients with non‐small cell lung cancer (NSCLC), with or without radiotherapy with curative intent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/full#CD011300-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011300-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Effect of immunotherapy for surgically treated NSCLC patients: main analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Overall survival rate, 1‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Overall survival rate, 2‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Overall survival rate, 3‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Overall survival rate, 5‐year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events (severe, grade &gt; 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.92, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Effect of immunotherapy for surgically treated NSCLC patients: main analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011300.pub3/references#CD011300-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011300.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011300-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011300-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011300-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011300-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011300-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011300-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011300-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011300-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011300-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011300\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011300\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011300\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011300\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011300\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011300.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011300.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011300.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011300.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011300.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717126419"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011300.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717126423"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011300.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db04c5a8f936e',t:'MTc0MDcxNzEyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 